Tumor-infiltrating lymphocytes (TILs) play a key role in the antitumor immune response and various types of immunotherapies. Recently, studies have shown that CD4+ T cells and CD8+ T cells are equally important for an efficient antitumor immune response, and in specific tumor settings, CD4+ T cell-mediated tumor killing effects can even outcompete that of CD8+ T cells.